Viragen to produce Multiferon at new Swedish facility

USA-based Viragen has said that its Swedish manufacturing facility inErsboda is on schedule to commence with the production of Multiferon (interferon alpha) in September. The company has been upgrading and expanding its production capabilities as a result of a more aggressive business direction for its natural human alpha interferon drug, it says. Viragen previously reported that it expects to report data later this year from studies evaluating Multiferon for the treatment of malignant melanoma.

"The combined manufacturing capabilities of our existing facility in Umea with our new facility in Ersboda will provide us with the compliance and capacity necessary to focus on our goal to make Multiferon the world's most-prescribed natural human alpha interferon," stated Viragen's chief executive Charles Rice. Construction of the Ersboda facility was completed earlier this year and it is currently undergoing validation required by the Swedish regulatory authorities, the firm notes.